Centauri Therapeutics selects first clinical candidate, for immunotherapeutic treatment of Gram-negative bacterial infections
Centauri Therapeutics Limited (Centauri), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, today announced the selection of its first clinical candidate in the ABX-01 programme. Based on the Company’s Alphamer® platform, the compound is designed to target serious Gram-negative bacterial…
Centauri Therapeutics awarded £1M grant under new PACE programme to advance immunotherapy platform in anti-infectives
Centauri is excited to announce that we have been selected to receive a £1M grant under the first round of @PACE-AMR funding which will support…
Centauri Therapeutics closes £24m Series A investment round
Centauri Therapeutics is delighted to announce new investment of £24m in antimicrobial research and appointment of new company directors. See attached press release
Centauri awarded follow-on CARB-X grant
Centauri Therapeutics Limited, an immunotherapy company focused on the treatment of infectious diseases, has been awarded a grant of up to $2.7 million USD (c.£2…